Infliximab induced chilblain lupus in a patient with rheumatoid arthritis.
Richez
Christophe
C
Dumoulin
Chantal
C
Schaeverbeke
Thierry
T
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000276:immunology; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D001323:Autoantibodies / Q000097:blood; D002647:Chilblains / Q000150:complications / Q000209:etiology* / Q000473:pathology; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D000069285:Infliximab; D008178:Lupus Erythematosus, Cutaneous / Q000150:complications / Q000209:etiology* / Q000473:pathology; D008875:Middle Aged; D011928:Raynaud Disease / Q000150:complications / Q000209:etiology / Q000473:pathology
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D001323:Autoantibodies; D000069285:Infliximab